Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

Stakeholder engagement analysis

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Theory-based case study with qualitative content analysis
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

VALPROIC ACID

Medical condition to be studied

Epilepsy
Population studied

Short description of the study population

Patient and healthcare professional representatives at the public hearing and dedicated stakeholder meeting for the valproate teratogenicity and risk management assessment by the Pharmacovigilance Risk Assessment Committee (PRAC) at EMA in 2017/2018.

Age groups

Adolescents (12 to < 18 years)
Adults (18 to < 46 years)

Special population of interest

Pregnant women

Estimated number of subjects

60
Study design details

Main study objective

(1) Analyse stakeholder input at public hearing and dedicated meeting for the 2017/18 EU procedure on valproate teratogenicity, (2) Draw proposals for enhancing PRAC engagement.

Outcomes

Stakeholder input content analysis findings and derived proposals for enhancing engagement between regulators, patients and healthcare professionals

Data analysis plan

Development of content analysis tool based on established theories with coding scheme and rules, testing of tool prior to application, peer examination of research design, data analysis applyig tool and adhering to coding rules
Documents
Study results
English (1.09 MB - PDF)View document